McGuireWoods has released its “HCPE 2026 White Paper: Private Equity in Healthcare and Life Sciences — An Updated Review of 20+ Select Subsector Investment Areas.”

The white paper examines investment trends, opportunities, and challenges across more than 20 healthcare and life sciences subsectors, including behavioral health, cardiology, women’s health, revenue cycle management, ancillary services, and life sciences infrastructure.

Key topics include the role of AI as a value-creation lever, the ongoing shift toward outpatient and home-based care, and the impact of regulatory and reimbursement pressures on deal activity.

Request your copy of the McGuireWoods white paper.

Bregal Sagemount has made a strategic growth investment in LSPedia, according to a news release.

LSPedia, founded in 2013 and with its U.S. headquarters in Farmington Hills, Michigan, is a provider of compliance, traceability and supply chain software to the pharmaceutical industry.

Sagemount, founded in 2012 and based in New York, is a growth-focused private equity firm that invests in healthcare IT and services and several other sectors. The firm seeks to invest $20 million to $400 million per equity transaction into control and non-control positions, typically as the lead investor.

Terms of the investment were not disclosed.

Albaron Partners has announced the close of its flagship fund.

The fund, Albaron Healthcare Opportunities I, closed with $185 million. It was oversubscribed.

Albaron, founded in 2017 and based in New York, is a lower middle market private equity firm. The firm focuses on investing in North American healthcare and healthcare services companies generating between $1 million and $10 million in EBITDA.

Salt Creek Capital has announced the acquisition of MML Diagnostics Packaging.

MML, founded in 1964 and headquartered in Troutdale, Oregon, is a contract manufacturer and packager of in-vitro diagnostic devices and single-use medical devices.

Salt Creek, founded in 2009 and based in Woodside, California, is a private equity firm that invests in the lower middle market across healthcare and other industries. The firm pursues a variety of investment types in U.S. and Canadian companies with EBITDA or annual cash flow greater than $750,000 and up to $20 million.

Terms of the acquisition were not disclosed.

Kinderhook Industries has completed its acquisition of Enhabit, according to a news release.

The deal was valued at approximately $1.1 billion.

Enhabit, founded in 2022 when it was spun off from Encompass Health Corp. and based in Dallas, is a national home health and hospice provider.

Kinderhook, founded in 2003 and based in New York, is a middle market private equity firm. The firm specializes in management buyouts of entrepreneurial-owned businesses operating in healthcare services and a few other sectors.

With the transaction completed, Enhabit’s common stock has ceased trading on the New York Stock Exchange and the company has become a privately held entity.

Water Street Healthcare Partners has announced the closing of its sixth private equity fund.

The fund, Water Street Healthcare Partners VI, closed with $1.9 billion in total capital commitments. The fund was oversubscribed and closed at its hard cap.

Water Street, founded in 2005 and based in Chicago, is a private equity firm focused exclusively on healthcare. The firm indicated that with the newly raised capital, it is seeking opportunities to invest in mid-market businesses specializing in medical products and diagnostics, pharmaceutical and life sciences, and healthcare services.

The secondary market has grown to roughly $220 billion as GPs and LPs scramble for liquidity in a private markets cycle stuck in a “worse distribution profile” for three and a half years. Chris Lawrence, managing partner at Labyrinth Capital Partners, joins McGuireWoods partner and host Geoff Cockrell to demystify GP-led secondaries. 

Chris breaks down continuation vehicles, strip sales and fund restructurings. He explains why secondary pricing ranges from par to as low as 72 cents on the dollar and makes the case that GP-leds are now a mature, institutionally accepted portfolio management tool.